Results 181 to 190 of about 898,128 (309)

Animals in child sleeping spaces and unimproved sanitation associated with diarrhea among young children in the Democratic Republic of the Congo: WASHmobile PICHA7 prospective cohort study. [PDF]

Trop Med Health
Bisimwa JR, Endres K, Sanvura P, Williams C, Thomas E, Perin J, Bisimwa L, Mwishingo A, Cikomola C, Bengehya J, Kulondwa JC, Mwene-Batu P, Maheshe G, George CM.   +13 more
europepmc   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Evan's blue dye test for detection of aspiration in tracheostomized patients. [PDF]

Cochrane Database Syst Rev
Ivaldi D, Burgos MA, Rico S, Varela LB, Díaz Menai S, Escobar Liquitay CM, Garegnani LI.   +6 more
europepmc   +1 more source

Retail food stores and Service and Hospital Employees Union, AFL-CIO, Local 399 (1973) [PDF]

, 1973

core   +1 more source

Tenecteplase Versus Alteplase for First‐Pass Reperfusion in Basilar Artery Occlusion Stroke Thrombectomy

Annals of Neurology, EarlyView.
Objective The first‐pass effect (FPE), defined as excellent reperfusion after a single attempt, is associated with improved outcomes in large vessel occlusion stroke. We evaluated whether intravenous tenecteplase (TNK) compared with alteplase (TPA) increases the likelihood of FPE in basilar artery occlusion (BAO).
Dylan N. Wolman, Rahul R. Karamchandani, Sina Hemmer, Tyler M. Bielinski, Nitin Goyal, Jeremy B. Rhoten, Mahesh V. Jayaraman, Christian T. Sidebottom, Bradley A. Gross, Alhamza R. Al‐Bayati, Mohamed F. Doheim, Matthew K. Tobin, Anoop Chinthala, Avi Gajjar, Justin Mascitelli, Matthew R. Webb, Jan‐Karl Burkhardt, Kyle W. Scott, Visish Srinivasan, Daniel Tonetti, Manisha Koneru, David J. Altschul, Dhrumhil Vaishnav, Sumeet Multani, Thana Theofanis, William J. Ares, Je Yeong Sone, Ramin Zand, Sasan Bahrami, Jiang Li, Gary Defilipp, Dale Strong, Radmehr Torabi, Krisztina Moldovan, Clemens M. Schirmer, Alexandra R. Paul, Bradley N. Bohnstedt, Raul G. Nogueira, Philipp Hendrix   +38 more
wiley   +1 more source

The Regulation of the Holy Hospital Hagios Panteleimon: Administrative and Ethical Framework under the Ottoman Hegemony. [PDF]

Cureus
Kazazis C, Nikolakakis I, Tentolouris N, Psycharis I, Karamanou M.   +4 more
europepmc   +1 more source

Rising Inpatient Demands for Inherited Metabolic Disorders: Impact on Pediatric Capacity

American Journal of Medical Genetics Part A, EarlyView.
Maria Paula Silva, Kirsten Havens, Katherine Arduini, Anne Kozek, Erika Vucko, Joel Charrow, Joshua Baker, Carlos E. Prada   +7 more
wiley   +1 more source

Prospective, Multicenter Evaluation of Transcarotid Artery Revascularization in Standard‐Risk Patients: 30‐Day Outcomes of the ROADSTER 3 Study

Annals of Neurology, EarlyView.
Objective To evaluate the real‐world safety and efficacy for standard surgical risk patients with extracranial internal carotid artery disease undergoing transcarotid artery revascularization. Methods ROADSTER 3 is a prospective, multicenter, single‐arm post‐approval study.
Jeffrey Jim, Meghan Dermody, Brian Peterson, Scott S. Berman, Nicolas J. Mouawad, Joseph Ricotta, Naveed Saqib, Peter Faries, Angela Martin, Joshua D. Adams, Uttam Tripathy, Daniel Calderon, David O'Connor, Rasesh Shah, Sumaira Macdonald, Marc L. Schermerhorn   +15 more
wiley   +1 more source

Impact of low-FODMAP diet on symptom relief in irritable bowel syndrome patients. [PDF]

Asia Pac J Clin Nutr
Luo Y, Xu Z, Li R, Zhang Q, Wu Z.
europepmc   +1 more source

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers   +33 more
wiley   +1 more source